China
Alioth Biotech, founded in 2021, is a fast-growing, technology-driven company dedicated to advancing pharmaceutical filtration and membrane separation solutions. Headquartered in China, the company leverages R&D expertise from teams based in Boston and Shanghai to develop innovative filtration membranes that enhance drug manufacturing processes.
Maintaining high standards, Alioth Biotech operates under ISO9001 and adheres to GMP guidelines, managing end-to-end manufacturing across expansive facilities. With a CNAS-accredited validation center and development labs, the company ensures the reliability and compliance of its solutions.
Recently, Alioth Biotech secured a significant CNY100.00M Series A investment on 10 October 2023, backed by prominent investors such as Legend Capital, Matrix Partners China, AstraZeneca CICC Medical Industry Fund, and Yi Shuishuishan. The influx of capital is set to propel their mission of becoming a "Reliable Partner in Pharma Filtration Processing" further.
